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 Introduction 
 Complications after lung transplantation have been 
widely reported, generally including the analysis of aetio-
logical factors  [1–7] . Some of these reports mention strat-
egies to prevent these complications. Very few formal 
guidelines exist for the practical management of lung 
transplant recipients (LTRs) with the exception of guide-
lines concerning infectious diseases and immunosup-
pression (IS)  [8–10] . Some single-institution or organisa-
tion documents offer comprehensive practical advice  [11–
13] . Reports on emergency department presentation and 
care of LTRs are scarce  [14–17] . We therefore aim to sum-
marise here some of the frequent emergency situations we 
encounter in our cohort of LTRs and report on how we 
deal with these situations. We are aware that medical 
practice varies strongly, influenced by local conditions. 
Therefore, this report is merely one possible way to ap-
proach these situations and has no claim of being best 
practice or universally applicable. It may stimulate dis-
cussions and research.
 The majority of frequently occurring medical emer-
gencies are related to the life-long, mostly triple immuno-
suppressive therapy and the multiple concomitant drugs 
resulting in long-term polymedication with several ad-
verse effects and drug interactions requiring a complex 
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medical management approach. The complications most 
frequently seen are due to infection, graft rejection and 
other drug-related effects such as bone marrow suppres-
sion or skin and bone lesions. For the purpose of our re-
port, we distinguish six groups of emergencies: (1) prob-
lems relating to IS, allograft rejection and polymedica-
tion; (2) respiratory tract infections and other infectious 
complications; (3) gastrointestinal emergencies; (4) car-
diovascular, renal and fluid balance problems; (5) pain 
and bone-related problems, and (6) surgery and other in-
vasive procedures. Most health problems in LTRs affect 
different organs simultaneously, requiring a more com-
plex medical approach. For symptom and problem man-
agement purposes, it is advisable to deal with the organ-
specific signs and symptoms and focus on immediate 
resolution without questioning the maintenance IS and 
concomitant drugs. However, it is important to remem-
ber that symptom presentation and severity is frequently 
blunted by the immunosuppressive therapy  [18] . There-
fore, preemptive strategies and frequently obtained labo-
ratory results, imaging studies or functional measure-
ments are required to assess the true clinical status of the 
patient and the response to treatment. The medical emer-
gencies discussed below will be dealt with, not in the or-
der of their frequency or severity, but in the order of the 
previously listed groups of emergencies related either to 
the aetiology or the organ system involved.
 Practically all LTRs transplanted in Zurich are pri-
marily managed long-term for all health issues by our 
lung transplant unit, which is part of the division for pul-
monary medicine at the University Hospital Zurich. In 
this setting, internists and pulmonologists in training are 
also involved, many without any previous contact with 
transplant medicine. This paper is meant to facilitate an 
understanding of the principles we respect in the man-
agement of LTRs. It is written for these junior doctors and 
specialists of other fields who collaborate with us to 
achieve optimal care for these patients by remaining in 
constant contact with the core care team at the transplant 
unit. Most of what we do at a practical level has been a 
result of trial and error over many years and has proven 
its importance over time without being based on ran-
domised clinical trials. Many practices are not strictly 
speaking compatible with the highest levels of evidence-
based medicine. Until such evidence becomes available, 
we respect the lower level of evidence or the recommen-
dations based on expert opinion and our experience.
 Home Spirometry, Lung Function over Time and 
Signs of Rejection 
 A key component for successful allograft and overall 
patient survival is adequate IS  [19] . Inadequate IS triggers 
acute graft rejection, which is sometimes clinically inap-
parent or presents with subtle signs and symptoms such 
as dyspnoea, low-grade fever, cough and malaise  [3, 13, 
20] . In the early stages of rejection, the only sign may be 
the lung function deterioration, i.e. reduction in forced 
expiratory volume in 1 s by  1 10% from the current base-
line or more on two consecutive days or hypoxaemia at 
rest or with exercise  [13] . The definitive diagnosis of al-
lograft dysfunction requires more specific investigations. 
Often a longer observation period is needed to confirm 
and classify the rejection and to differentiate between 
acute and chronic forms  [2, 20–22] . In general, patients 
are instructed to perform home spirometry on a daily ba-
sis and are advised to contact the transplant team or phy-
sician if the lung function deteriorates  [23, 24] . The eval-
uation of lung function loss and the predominant aetio-
logical aspect requires experience with this complex 
topic. Some reasons and aetiologies are listed in  table 1 . 
Identification and early treatment of suspected or likely 
acute rejection is the key step in early management of this 
problem. Technical issues such as a defective home spi-
rometer or a suboptimal spirometry technique have to be 
excluded. Definitive evaluation must be performed by the 
lung transplant physician as soon as possible. Anti-rejec-
tion treatment is only given if all other causes of allograft 
dysfunction have been excluded or treated appropriately 
 [3, 13] . This is especially true for a respiratory tract infec-
tion, as it may present in a similar way. Clinical assess-
ment and non-invasive evaluations (imaging, lung func-
Table 1.  Common reasons for acute lung function deterioration 
in LTRs
Infection of respiratory tract
Acute allograft rejection with or without visible endobronchial
secretions/mucus plugging
Bronchial complications: anastomotic stenosis, malacia
Chest or abdominal pain
Chest wall herniation
Pleural effusion
Intra-abdominal process (ascites, stool retention/coprostasis)
Aspiration (after vomiting)
L ung function here refers primarily to forced expiratory vol-
ume in 1 s; however, evolution of forced vital capacity and carbon 
dioxide transfer factor are considered as well.
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tion) do not reliably distinguish between infection and 
rejection  [13, 25] . Nevertheless, work-up for possible in-
fection or rejection will include history, clinical examina-
tion, lung function tests and a high-resolution computed 
tomography (HRCT) of the lung (with expiratory images, 
without using a contrast agent)  [13] . A typical pitfall is to 
rely on a chest radiograph to exclude such a pathology 
 [17] . A chest X-ray may only show features suggestive of 
advanced stages of rejection (bronchiectasis, pleural effu-
sion) or help detect alternative diagnoses such as cardiac 
failure  [26] . Since the early diagnosis and treatment of 
infection or rejection is essential, HRCT images are eval-
uated to make alternative diagnoses and choose the loca-
tion for biopsy sampling at bronchoscopy, with subse-
quent sample assessment by a transplant-experienced 
 pathologist  [20, 26–28] . HRCT alone is not sufficiently 
specific and sensitive to reliably diagnose rejection. In 
acute rejection, HRCT findings may include ground-
glass opacities (often with basal distribution), peribron-
chial cuffing, septal thickening and new or more exten-
sive pleural effusion. In chronic rejection, dilated bron-
chi, bronchiectasis, mosaic attenuation and air trapping 
(on expiratory scans, more pronounced in the lower 
lobes) may be observed  [27, 29] . Bronchoscopic biopsies 
may contribute to the tissue diagnosis of acute rejection 
 [29, 30] . Chronic rejection can be diagnosed based on 
functional criteria  [2, 3, 21, 22] , and if tissue diagnosis is 
sought, then surgical biopsy is more likely to be diagnos-
tic  [13] .
 Immunosuppression 
 Life-long triple IS is standard after lung transplanta-
tion  [19] . At our centre, cyclosporine A, mycophenolate 
mofetil (MMF) and prednisone are predominantly used. 
Only exceptionally are tacrolimus or everolimus used in 
our LTRs. Beyond the early transplant phase, the IS is ti-
trated to the lowest acceptable dose of the immunosup-
pressive drugs that prevents allograft rejection. In this 
process, the cyclosporine dose is most closely monitored, 
with measurement of serum drug levels, often termed 
therapeutic drug monitoring (TDM)  [31] . Dose adjust-
ments are required especially when drug regimens are 
changed and drug interactions occur  [2] . The adverse ef-
fects of cyclosporine need to be taken into account when 
the patient’s clinical condition deteriorates, for example 
if the renal function is progressively impaired  [2, 32] . As 
is common practice elsewhere, we taper the steroid dose 
to a 0.1–0.15 mg/kg/day maintenance dose beyond 12 
months after transplantation and additionally aim for a 
suppressed lymphocyte count as a marker for the thera-
peutic effect of MMF. In our setting, leucopaenia is most 
often the dose-limiting factor for MMF dosing. Only as 
an indicator of compliance and intestinal drug uptake do 
we occasionally measure MMF drug levels. TDM-orient-
ed dosing of MMF is a debated issue, and data for LTRs 
are insufficient to strongly support any particular TDM-
based strategy  [10, 33–35] . We lower the cyclosporine 
dose during the first year after transplantation under 
constant monitoring for signs of acute rejection [trough 
drug levels (C0) approx. 80–160   g/l and target peak 
drug levels (C2; 2 h after drug intake) 500–700   g/l 12 
months after transplantation if renal function is normal]. 
If kidney impairment occurs, reduction of the nephro-
toxic immunosuppressive drugs and other drugs is re-
quired, aiming for a good allograft function and preven-
tion of further deterioration of renal function  [19, 31, 32] .
 The ‘fine-tuning’ of IS for each individual patient is a 
process that occurs over months and years, an integra-
tive process whereby previous laboratory results influ-
ence the overall strategy. A ‘one strategy fits all’ approach 
is hardly ever possible. Area under the curve measure-
ments for cyclosporine are periodically performed in or-
der to assess drug exposure and drug peak timing and 
serve to fine-tune the dosing and monitoring parameters 
(determine for example if C1 or C2 is the best ‘peak’ time 
point)  [31] . Frequently, multiple dose adjustments are re-
quired based on allograft function, pathology results 
from trans-bronchial biopsies obtained at surveillance 
bronchoscopy and consideration of interactions with 
concomitant medications and potential for adverse 
events. Typically, co-medication with itraconazole influ-
ences cyclosporine drug levels as well as the timing and 
shape of the peak curve. Despite extensive efforts to 
maintain optimal IS, there are multiple factors that lead 
to chronic lung allograft dysfunction, with bronchiolitis 
oblite rans syndrome (BOS) being the most common one 
 [22, 36] . BOS, the physiological correlate of histological-
ly proven bronchiolitis obliterans, affects up to 50% of 
surviving LTRs by 5 years after transplantation  [7] . BOS 
is defined by a  1 20% decrease in forced expiratory vol-
ume in 1 s from the post-transplantation baseline after 
the exclusion of other causes such as acute airway infec-
tion. It is classified into different stages depending on the 
severity of lung function impairment (BOS grades 1–3) 
 [3, 21, 22] . Causes, mechanisms and therapeutic ap-
proaches to BOS are beyond the scope of this article  [2–5, 
22, 36] . In the case of suspected BOS, expert referral (to 
a transplant centre) is strongly advised.
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 Intravenous IS and Laboratory Investigations 
 Since adequate and uninterrupted IS is one of the key 
features of BOS prevention, all effort must be taken to 
optimise IS. In situations where oral or enteral (via duo-
denal or jejunal tube) drug application is either inade-
quate or not feasible, IS medication has to be given intra-
venously. We then replace prednisone by methylpredni-
sone (in equipotent doses, i.e. nominally a dose reduction 
of 20%), give the identical MMF dose intravenously (1: 1) 
and reduce the intravenous cyclosporine dose (given over 
4 h) nominally to 1/4 to 1/3 of the oral dose. Close moni-
toring of the cyclosporine trough level (C0) and kidney 
function is recommended for this situation.
 Because of the complexity of LTRs and the extensive 
co-medication, routine and emergency laboratory inves-
tigations for hospitalised patients and outpatients must 
cover the following: electrolytes (sodium, potassium, 
magnesium, phosphate, calcium), kidney function (cre-
atinine, urea), C-reactive protein, liver function, biliru-
bin, lactate dehydrogenase, creatine kinase, full blood 
count including differential white blood cell count and 
cytomegalovirus (CMV)/Epstein-Barr virus (EBV) se-
rum blood counts (PCR)  [28, 32] . We aim to verify both 
cyclosporine trough (C0) and peak levels (C2, or if appro-
priate C1).
 Standard and Special Medication 
 When more than 15 different drugs are used daily 
(polymedication) over longer periods of time, then drug 
interactions (with increased or decreased drug effects) as 
well as increased drug toxicity or adverse events must be 
considered. It is advisable to use drugs that have a low 
potential for drug interaction or drugs with known inter-
action patterns in the situation of LTRs. We therefore fo-
cus on a limited number of drugs with known character-
istics when used in polymedicated LTRs. Lists of these 
frequently used drugs are shown in  tables 2 and  3 . For 
every other drug used, the interaction potential and pos-
sible adverse events (including the nephrotoxic potential) 
should be considered prior to its application ( table  4 ). 
Both calcineurin inhibitors (CNIs), cyclosporine and ta-
Table 2.  Typical medication used in the first year after transplantation
Active ingredient Typical dosage Main indication/function
Cyclosporine A Q12H, dose according to TDM IS
MMF1 1.5 g Q12H IS
Prednisone 5–7.5 mg QD IS
Itraconazole1, 2 100–200 Q12H antifungal prophylaxis
Valganciclovir1 450 mg BID CMV prophylaxis 
Valacyclovir 500 mg BID herpes virus prophylaxis 
Amphotericin B INHAL 10 mg BID antifungal prophylaxis
Sulfamethoxazole-trimethoprim1 0.5–1 tablet TIW PJP prophylaxis
Calcium-vitamin D3 1 g QD osteoporosis prophylaxis
Pantoprazole 40 mg Q12H PPI/antacid
Esomeprazole1, 2/omeprazole1, 2 40 mg Q12H PPI/antacid
Domperidone 10 mg TID AC prokinetic/anti-reflux
Magnesium 10 mmol TID supplementation
Ibandronate IV 3 mg 3-monthly osteoporosis treatment
Zoledronic acid IV 5 mg yearly osteoporosis treatment
Paracetamol 1 g PRN analgesia
Metamizole 500 mg PRN analgesia
Macrogol 3350 6–18g/day laxative
A ll drugs are taken orally unless stated otherwise. Some dosages may have to be adjusted to underlying or co-morbid conditions 
such as CF, kidney dysfunction, bone marrow suppression or body weight. QD = Once a day; BID = twice a day; TID = three times a 
day; Q12H = every 12 h; PRN = as needed; AC = before meals; IV = intravenous route; INHAL = inhalation; TIW = three times a week; 
PJP = pneumocystis jiroveci pneumonia.
1 Drug may cause cytopaenia.
2 Introduction of this drug interacts with cyclosporine metabolism by increasing cyclosporine levels. Both drugs should be given 
at fixed time points, and for cyclosporine, TDM is recommended.
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crolimus, have a relevant nephrotoxic effect that must be 
considered at all times in LTRs. Typically, the cyclospor-
ine dose is affected by a number of drugs with common 
metabolic pathways in the liver (e.g. clarithromycin or 
itraconazole), so that introduction of these drugs requires 
close monitoring of cyclosporine drug levels and adjust-
ment of the dose about 72 h after introducing the new 
drug (often a dose reduction of cyclosporine by about 1/3 
is needed). Use of clarithromycin in LTRs with the cur-
rent IS regimen is considered dangerous by some trans-
Table 3.  Add-on medication for specific situations, emergencies or co-morbid conditions
Active ingredient Typical dosage Main indication/
function
Ciprofloxacin 500 mg BID antibiotic
Amoxicillin-clavulanate 1 g BID antibiotic
Levofloxacin 500 mg QD antibiotic
Metronidazole1, 2 500 mg TID antibiotic
Meropenem1 IV 1 g Q8H antibiotic
Piperacillin-tazobactam1 IV 4.5 g Q8H antibiotic
Teicoplanin IV 100–200 mg QD, TDM antibiotic
Linezolid 600 mg BID antibiotic
Tobramycin INHAL or IV 80 mg or IV 150 mg antibiotic
Colistin INHAL 1 Mio BID antibiotic
Caspofungin IV 50 mg QD antifungal 
Oseltamivir 75 mg BID antiviral
Vitamin D 300 IU QD supplementation
Vitamin E 300 mg QD supplementation
Multivitamins QD supplementation
Metoprolol 25–100 mg anti-hypertensive
Doxazosin mesylate 4–8 mg anti-hypertensive
Lisinopril 5–20 mg anti-hypertensive
Clonidine 150–450 mg anti-hypertensive
NAC 10–20% orally laxative
Diatrizoate meglumine and
diatrizoate sodium 10–50 ml laxative
Macrogol 4000 0.1–1 litre PRN laxative
Amiodarone2 200 mg QD anti-arrhythmic
Pravastatin 20–40 mg QD dyslipidaemia
Amylasum, lipasum, proteasum
pancreatis TID pancreas enzymes
Ranitidine 150 mg Q12H antacid
Sertraline 50–75 mg QD antidepressant
Escitalopram 10 mg QD antidepressant
Pipamperone 40 mg QD HS sleep disturbance
Levetiracetam 500 mg Q12H anti-epileptic
Gabapentin 200–1,200 mg neuropathic pain
Clarithromycin2 125–250 mg Q12H immunomodulation
Azithromycin 250 mg TIW immunomodulation
Tacrolimus Q12H, dose according to TDM IS
Everolimus Q12H, dose according to TDM IS
A ll drugs are taken orally unless stated otherwise. Some dosages may have to be adjusted to underlying or co-morbid conditions 
such as CF, kidney dysfunction, bone marrow suppression or body weight. QD = Once a day; BID = twice a day; TID = three times a 
day; Q8H = every 8 h; Q12H = every 12 h; HS = at bedtime; PRN = as needed; IV = intravenous route; INHAL = inhalation; Mio = 
million; TIW = three times a week. 
1 Drug may cause cytopaenia.
2 Introduction of this drug interacts with cyclosporine metabolism by increasing cyclosporine levels. Both drugs should be given 
at fixed time points, and for cyclosporine, TDM is recommended.
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plant centres due to the described interaction with the 
possibility of strongly increasing cyclosporine toxicity 
 [12] . The macrolide azithromycin has a similar bacteri-
cidal and immunomodulatory efficacy without pro-
nounced interaction potential and is therefore safer and 
considered the drug of choice to counteract BOS in LTRs, 
especially in those with neutrophilic bronchoalveolar la-
vage (BAL) fluid  [3, 22, 37, 38] . Azole-based antifungal 
treatment is prone to interactions (especially with rifam-
picin), so that insufficient drug levels may result despite 
regular intake. These situations require frequent TDM 
and dose adjustments. In situations of increased risk of 
invasive fungal infections (augmented IS) or documented 
fungal infection, we consider treating temporarily with 
caspofungin, bearing in mind that it does not cover zy-
gomycosis infection  [39] . In contrast to guidelines and 
common practice elsewhere, we hardly ever use flucon-
azole or voriconazole  [40–42] .
 For reasons of drug interaction stability, the mainte-
nance drugs are taken at fixed intervals and time points 
(generally 12-hourly together with cyclosporine). Certain 
proton pump inhibitors (PPIs) also interact with cyclo-
sporine; thus, it is not advisable to switch PPIs unless ex-
ceptional reasons exist and close TDM can be performed 
 [39] . For similar reasons, we do not change or perma-
nently stop giving drugs with known interactions, even if 
a new drug is introduced to treat an intercurrent problem 
(infection). We accept the transient overlap of treatment. 
For example, we do not pause itraconazole for reasons of 
drug interaction balance when we treat a fungal infection 
with caspofungin intravenously. It also does not make 
sense to pause azithromycin or clarithromycin given for 
immunomodulation (not infection) in BOS when anoth-
er antibiotic is transiently introduced  [5] . This is a com-
mon pitfall for physicians not familiar with the treatment 
concepts established for LTRs. The need for accurate pan-
creas enzyme replacement therapy in cystic fibrosis (CF) 
patients following lung transplantation requires particu-
lar attention; variations in dosing and stool frequency 
may strongly influence intestinal drug uptake and there-
fore change drug levels  [39] . If insufficient drug levels for 
IS or antifungal prophylaxis are observed in these pa-
tients, intravenous IS and antifungal treatment must be 
considered in order to prevent allograft rejection or fun-
gal infection  [43] . For general physicians without experi-
ence in transplant medicine, it is sometime surprising to 
realise that seemingly ‘harmless’ drugs might cause seri-
ous complications due to non-anticipated interactions 
and subsequent adverse events (e.g. diclofenac with sub-
sequent renal failure, fluconazole with subsequent in-
creased cyclosporine toxicity).
 Cytopaenia 
 Polymedication and IS very frequently lead to cyto-
paenia due to bone marrow suppression  [5, 13] . Most fre-
quently, leucopaenia, lymphopaenia, neutropaenia and 
anaemia are observed, and sometimes also thrombocy-
topaenia. Lymphopaenia is aimed for as part of the im-
munosuppressive strategy and it is therefore monitored 
closely (by obtaining the differential white blood cell 
count) to assess the therapeutic effect of MMF. LTRs are 
generally treated with more than one drug that tends to 
cause cytopaenia as an adverse event. This leads to an in-
creased incidence of cytopaenia (generally leucopaenia). 
When this occurs, the culprit drugs must be reduced (or 
stopped) immediately in order to allow for recovery from 
Table 4.  Drugs affecting cyclosporine and tacrolimus levels or 
with nephrotoxic effects
Increase levels of cyclosporine and tacrolimus (leading to toxicity)
Calcium channel antagonists diltiazem, verapamil, nicardipine
Antibiotics erythromycin, clarithromycine, 
doxycycline
Antifungals itraconazole, ketoconazole, 
fluconazole, voriconazole
Gastrointestinal medications cimetidine, ranitidine, 
metoclopramide
Other drugs amiodarone, allopurinol
Decrease levels of cyclosporine and tacrolimus (leading to rejection)
Antibiotics nafcillin, sulfamethoxazole-
trimethoprim IV, isoniazid, 
rifampicin
Anticonvulsants phenytoin, phenobarbital, 
carbamazepine
Other drugs Hypericum perforatum (St. John’s 
wort) 
Increase nephrotoxicity without changing drug levels
Antifungals/antivirals amphotericin B, acyclovir, 
valganciclovir
Antibiotics aminoglycosides, sulfamethoxa-
zole-trimethoprim p.o.
Non-steroidal anti-inflammatory drugs (all formulations)
Radiocontrast agents
Ranitidine
M odified from Knoop et al. [2] and Playe and Heilpern [15].
IV = Intravenous; p.o. = orally.
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bone marrow suppression. We primarily reduce (or 
pause) the following drugs: MMF, valganciclovir, sulfa-
methoxazole-trimethoprim, metronidazole and intrave-
nous antibiotics (i.e. piperacillin-tazobactam or merope-
nem). Sometimes the PPI is reduced as well although it 
very rarely causes cytopaenia. It might be advisable to 
give alternative drugs such as ranitidine to replace the PPI 
and to reduce the dose of the intravenous antibiotic. If we 
pause valganciclovir, we normally start the patient on val-
acyclovir instead  [44] . After recovery from cytopaenia, 
we reintroduce the drugs carefully. During this period, 
frequent monitoring of white blood cell counts is manda-
tory. Similarly, in progressive renal impairment, drug 
doses have to be adapted accordingly, i.e. sulfamethoxa-
zole-trimethoprim (1/2 tabs), valganciclovir or antibiotic 
doses need to be reduced, paused or replaced by less 
nephrotoxic medication.
 Approach to Respiratory Tract Infection and 
Infection of Unclear Origin 
 Respiratory tract infection is by far the most frequent 
emergency observed in LTRs  [4, 15, 17] . This is mainly 
due to profound IS and the fact that the transplanted or-
gan remains in constant contact with the environment. 
Even minor respiratory symptoms such as throat or nose 
irritation/pain, runny nose, increased sneezing or a slight 
cough should prompt investigations, as early treatment 
may be crucial to prevent prolonged illness. We generally 
perform nasopharyngeal swabs (NPS; obtained nasally if 
nasal symptoms are prominent, otherwise pharyngeal 
swabs are taken) for viral and bacteriological examina-
tion and then immediately initiate empiric anti-infective 
therapy with moxifloxacin (1  ! 400 mg daily) and in the 
influenza season additionally oseltamivir (2  ! 75 mg, or 
1  ! 75 mg daily in LTRs with renal impairment) pending 
NPS results  [45] . Many centres have a more restricted use 
of oseltamivir. It remains to be determined what signs 
and symptoms in LTRs will justify its beneficial use and 
also be cost-effective. We avoid macrolides as short-term 
antibiotic treatment because of drug interactions ( ta-
ble 4 ). If laboratory results or lung function deterioration 
suggest more severe infection, we consider the early start 
of intravenous antibiotic treatment. In elderly patients 
with co-morbidities or signs of more severe infection, we 
prefer hospital admission for inpatient treatment and 
work-up. If viral NPS results return negative, we stop 
 oseltamivir immediately and generally stop the empiric 
moxifloxacin treatment after 1 week. If symptoms and/or 
lung function deterioration persist or inflammatory signs 
are unexplained, we obtain additional samples from the 
respiratory tract (sputum if available), and we consider 
performing a bronchoscopy for additional sampling and 
even trans-bronchial biopsies if the situation remains un-
clear  [9] . The NPS and BAL fluid analysis includes gen-
eral bacteriology and mycology (direct stains, culture and 
drug sensitivity testing) as well as virological investiga-
tions by PCR for the following viruses: adenovirus, en-
terovirus, influenza A and B (including H1N1), parain-
fluenza, respiratory syncytial virus A and B (RSV) and 
rhinovirus  [28, 46] . Recently, we added coronavirus to 
this panel, as it is frequently detected in LTRs  [47] . De-
pending on the clinical and radiological findings, we ad-
ditionally send BAL and/or bronchial washes for detec-
tion of CMV, herpes simplex virus, varicella zoster virus, 
 Nocardia, Legionella, Pneumocystis jiroveci and  Myco-
bacteria  [45, 46, 48, 49] . In documented respiratory syn-
cytial virus infection and sometimes in prolonged para-
influenza virus infection, we start oral ribavirin therapy 
and monitor virus elimination as well as adverse events 
(typically anaemia)  [50, 51] . Fungal infections are com-
mon in LTRs and sometimes occur despite apparently ad-
equate antifungal prophylaxis. In the work-up of severe 
deterioration of pulmonary function, HRCT imaging 
and bronchoscopic sampling are required for the diagno-
sis of allograft rejection or infection, for example invasive 
fungal infection  [26–29, 52] . When additional antifungal 
treatment is required, we prefer caspofungin due to its 
favourable safety profile. We thereby bear in mind the 
fungal infections not covered effectively by caspofun-
gin such as zygomycosis, cryptococcosis  and Geotrichum 
 [53] .
 In situations of an unclear infectious focus and/or un-
explained inflammatory signs in laboratory results (ele-
vated white blood cell count, C-reactive protein or sedi-
mentation rate), infection and rejection must be consid-
ered. A good rule of thumb is to consider infection high 
in the differential diagnosis of any new sign or symptom 
in LTRs  [28] . We undertake a general diagnostic work-up 
consisting of additional laboratory investigations such as 
quantitative serum CMV and EBV viral load (by PCR), 
sampling of NPS (see above), removal (or replacement) of 
intravenous lines and culture of the catheter tip as well as 
urine and stool cultures including the detection of  Clos-
tridium difficile and its toxins  [45] . Depending on the sit-
uation, additional investigations may be ordered such as 
blood cultures and sputum culture (including mycobac-
teria), abdominal X-ray, CT of the thorax and abdomen 
and sonography of the abdomen or pleura. Bloodstream 
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infection must be considered even in the afebrile LTR 
 [16] . We always ask for CT scans without intravenous 
contrast agent due to the substantially increased risk of 
renal failure in LTRs. CMV and EBV reactivation must 
always be considered in such situations, so quantitative 
viral load measurements are requested. CMV reactiva-
tion in the first year after transplantation is common and 
may occur despite adequate prophylaxis under specific 
circumstances  [8, 54, 55] . CMV pneumonia is a feared 
complication as it is a risk factor for BOS development 
 [22] . Knowledge of the incidence and timing of various 
types of infection and the responsible pathogens should 
help in the prevention, early detection and initiation of 
therapy in LTRs  [56–58] . Multiresistant bacteria are fre-
quently encountered in end-stage lung disease, and fre-
quently these bacteria persist in the airways after trans-
plantation (e.g.  Pseudomonas aeruginosa ). Antimicrobial 
treatment must take into account the presence of these 
organisms  [40, 46, 53] .
 Empiric infection treatment for early or minor symp-
toms of respiratory or unlocalised infection would usu-
ally include oseltamivir (in the influenza season) and 
 either moxifloxacin or amoxicillin-clavulanate or cip-
rofloxacin, depending on the suspected organism or pre-
viously detected bacteria. If there is any doubt, we gener-
ally prefer the application of intravenous antibiotics, 
i.e. empirical piperacillin-tazobactam to treat Gram- 
negative pathogens and the addition of teicoplanin in 
a suspected bloodstream infection to treat Gram-positive 
pathogens. Rarely do we use vancomycin, the drug of 
choice for this situation according to the guidelines  [45] . 
In the case of recent antibiotic treatment, we consider  C. 
difficile as responsible for gastrointestinal infection and 
add metronidazole empirically. We have a low threshold 
to add intravenous antifungal treatment (i.e. caspofun-
gin) to the treatment regimen, in particular if previous 
sampling is suggestive of a fungal airway infection  [52, 53, 
59] .
 If LTRs suffer from frequent episodes of infections, 
hypogammaglobulinaemia (often due to immunosup-
pressive therapy) needs to be detected by requesting mea-
surement of immunoglobulin G levels. If the immuno-
globulin G level is found to be below the normal range 
( ! 7.3 g/l), we give intravenous immunoglobulins to en-
hance the body’s immune defence against infections. 
This is especially important in documented CMV dis-
ease, infection with encapsulated bacteria (e.g.  Klebsiella ) 
and some viral infections  [46, 55] . In suspected infection, 
we initially reduce the MMF dose by 1/3 to 1/2 of the 
maintenance dose depending on the severity of the ex-
pected infection and the net IS of the patient. Some cen-
tres temporarily interrupt MMF therapy at the onset of 
suspected infection.
 Gastrointestinal Tract Emergencies 
 After respiratory tract infections, gastrointestinal 
problems are the second most frequent emergency situa-
tion in our LTRs  [5, 60, 61] . The underlying diagnosis (e.g. 
CF) may contribute substantially to this, but these emer-
gencies are observed in all patient groups and are partly 
related to the polymedication leading to decreased gas-
trointestinal motility and increased food transit time. 
 Intra-abdominal complications strongly affect survival 
rates in LTRs  [60] . Profound IS hampers the diagnosis of 
many complications by blunting symptoms  [18] . This is 
especially true for abdominal emergencies.
 Among the most frequent problems observed in LTRs 
are obstipation and intestinal obstruction. They are 
therefore frequently discussed at routine outpatient and 
emergency visits. Abdominal X-rays are very useful for 
unclear vomiting, abdominal pain or suspected obstipa-
tion as the latter is not always easily diagnosed on clinical 
grounds. Imaging of stool retention also helps convince 
patients that consequent treatment is required. Intestinal 
motility is decreased and gastrointestinal transit is re-
duced by the standard medication so that laxative treat-
ment is generally needed to loosen stool consistency and 
allow for regular daily stools. Some patients require com-
binations of laxatives, including agents used for bowel 
preparation. This is especially important in distal intes-
tinal obstruction syndrome, a condition typically ob-
served in CF patients  [62] . For this syndrome, we also give 
highly concentrated N-acetylcysteine (NAC) orally (gen-
erally 1 ampoule/vial of NAC 10%/20% in orange juice) 
and/or as an enema (4 vials of NAC 20% in 500 ml of NaCl 
0.9%) in order to re-establish intestinal passage. NAC re-
duces stool consistency. Early aggressive medical therapy 
is indicated to prevent worsening of the clinical condition 
and possibly surgical intervention as the ultimate treat-
ment option (enterotomy and faecal disimpaction). Phy-
sicians and LTRs alike generally underestimate the po-
tential dangers of unresolved obstipation.
 Vomiting within 1 h of taking immunosuppressive 
medication may severely affect the systemic levels of IS. 
Therefore, patients are instructed to take the immuno-
suppressants a second time if this occurs and call the 
transplant team for advice. Vomiting may be related to 
insufficient or inverse upper gastrointestinal motility but 
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can also be a consequence of gastroparesis, decreased 
lower intestinal motility or bowel obstruction. Vomiting 
may lead to micro- or even macroaspiration, which is 
likely to contribute to the development of allograft rejec-
tion  [37, 63] . Treatment of vomiting is guided by the po-
tential causes. However, symptomatic treatment is initi-
ated early in order to prevent drug malabsorption and 
aspiration. Frequently, various anti-emetics are tried un-
til a full response to treatment is achieved. In prolonged 
vomiting refractory to most interventions and other situ-
ations where oral uptake is transiently not possible, we 
have a post-pyloric tube inserted by the gastroenterolo-
gist so that medication and feeds can be given intestinal-
ly. Nasogastric tubes are very rarely used, exclusively to 
evacuate gastric contents in initially unclear cases.
 Diarrhoea is very frequent, sometimes as a result of the 
medication (magnesium, MMF or laxatives), but it may 
have more sinister causes such as  C. difficile,  norovirus or 
parasitic intestinal infection. Therefore, we maintain a 
low threshold for performing stool analysis, especially to 
rule out clostridial infection. For patients with recurrent 
clostridial infections or high suspicion of antibiotic-asso-
ciated diarrhoea, we preemptively treat with oral metro-
nidazole pending stool analysis results  [45] . Treatment 
focuses on likely causes and very rarely includes symp-
tomatic treatment with anti-diarrheal medication. No 
preparations containing  Saccharomyces boulardii or oth-
er probiotics are used at any time. Paradoxical diarrhoea 
is more frequently seen in LTRs, sometimes even associ-
ated with vomiting. Frequently, it is difficult to convince 
patients (and doctors) of the fact that constipation or dis-
tal intestinal obstruction syndrome is present and conse-
quent laxative treatment is needed despite the patient 
passing loose stools. Abdominal X-rays are very helpful 
in these situations to demonstrate stool accumulation, 
exclude other intra-abdominal pathologies (free air?) and 
prompt patients to use laxative medication consequently.
 Rigorous fluid substitution is mandatory during epi-
sodes of vomiting and diarrhoea. Close monitoring of 
drug levels is recommended, since drug absorption is fre-
quently altered by these conditions.
 Abdominal pain and other signs and symptoms of in-
testinal dysfunction are much less frequently observed 
than in non-transplant patients, even in the presence of 
severe intra-abdominal pathology. This is due to the 
blunting of symptoms by IS  [18] . If pain occurs, it poten-
tially indicates a more advanced stage of intestinal prob-
lem. We maintain a low threshold for urine culture be-
cause typical symptoms of urinary tract infection are rare 
in LTRs, for men and women alike. We perform abdom-
inal or renal ultrasound as our second-line investigation. 
Causes of abdominal pain are frequently bowel obstruc-
tion, colitis of various aetiologies (CMV,  C. difficile, di-
verticulitis) and colon perforation. Less often cholecysto-
lithiasis, biliary tract disease or pancreatitis are diag-
nosed  [60, 61, 64, 65] .
 Gastro-oesophageal reflux (GOR) is very common 
among LTRs for a number of reasons (e.g. altered tho-
racic mechanics, effects of immunosuppressive drugs on 
lower oesophageal sphincter function, vagal nerve dys-
function following surgery and possibly an underlying 
diagnosis, e.g. scleroderma)  [60] . We therefore promote 
anti-reflux measures for all LTRs, i.e. entire bed with el-
evated head-end, avoiding lying down within 2 h of eat-
ing and drinking, and avoiding known promoters of 
GOR such as alcohol and caffeine-containing beverages 
in the evening. In addition, all our patients receive anti-
GOR medication (i.e. domperidone, PPI, sometimes ra-
nitidine). Weight reduction and preventive measures 
during surgical procedures are further important mea-
sures to prevent aspiration episodes and their negative 
consequences on long-term allograft survival. For our 
LTR cohort, we do not generally perform anti-GOR sur-
gery (fundoplication), even though such an approach has 
been advocated by other lung transplant programs  [66] .
 Pain and Bone-Related Problems 
 Since osteoporosis or osteopaenia is common among 
LTRs, even in young patients, they receive appropriate 
treatment with daily calcium and vitamin D3 supple-
ments  [67] . Most LTRs also receive a bisphosphonate. De-
spite these measures, fractures occur even after minor 
trauma. Any pain that may be related to the skeletal sys-
tem is investigated with X-ray imaging, and if this is in-
conclusive, we perform MRI or CT scanning, whatever 
appears more appropriate. We encourage physical exer-
cise such as walking and cycling or the use of the home 
trainer. We quite often investigate the onset of foot pain 
and find a metatarsal fracture. Conservative treatment 
for fractures is attempted in most cases, and prolonged 
bone healing is anticipated.
 Pain in the Achilles tendon, or achillodynia, is some-
times seen in patients on long-term treatment with quin-
olones (e.g. ciprofloxacin). If the quinolone is not discon-
tinued at an early stage it may lead to partial or complete 
rupture of the Achilles tendon. In these LTRs, quinolones 
should be avoided by all means in future antibiotic treat-
ments.
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 Treatment of pain in the presence of nephrotoxic 
drugs is a challenge, since we aim to preserve renal func-
tion as well as intestinal motility. Usually analgesia is ob-
tained with paracetamol and metamizole or a combina-
tion of the two, whereby maximal dosing may be neces-
sary. Only very exceptionally do we use opioids, such as 
tramadol or fentanyl, due to the frequent adverse effects 
on intestinal function and the loss of aerodigestive re-
flexes. Non-steroidal anti-inflammatory drugs are not 
used in LTRs due to the potential detrimental effects on 
renal function  [32] . We treat localised pain with lidocaine 
patches, and in rare cases of refractory pain, we addition-
ally use antidepressants or a neuroleptic drug (e.g. gaba-
pentin).
 In the case of a minor superficial trauma or lesions to 
the skin or mucosa (e.g. dental work), we recommend 
prophylactic treatment with amoxicillin-clavulanate (3 g 
1 h prior to a dental procedure and 1 g 3 h thereafter) 
or giving the drug at the normal dose for 1 week starting 
24 h before any minor intervention (e.g. skin biopsy) or 
after any kind of minor accidental skin lesion (antibiotic 
prophylaxis)  [68–70] . The best prophylactic antibiotic 
strategy in LTRs remains to be determined.
 Cardiovascular and Fluid Balance Emergencies 
 Arterial hypertension is increasingly observed the 
longer the interval following transplantation and the old-
er the LTR  [5, 7, 71] . A hypertensive crisis may be consid-
ered a medical emergency and requires intervention. We 
tend to accept slightly higher blood pressures than gener-
ally recommended for non-transplanted patients, partic-
ularly in LTRs with known orthostatic dysregulation, as 
they are otherwise prone to falls. We generally recom-
mend obtaining blood pressure measurements exclusive-
ly in the sitting position and adjusting anti-hypertensive 
medication based on these measurements only. This 
needs to be emphasised in hospitalised LTRs in order to 
prevent orthostatic hypotension and its consequences. 
We limit anti-hypertensive drugs to a number of known 
drugs with reduced interaction and adverse event poten-
tial ( table  3 ). Calcium antagonists such as amlodipine 
tend to cause oedema and orthostatic hypotension in our 
LTRs, so we tend to avoid this additional problem by us-
ing other anti-hypertensive drugs. Signs and symptoms 
of coronary heart disease and heart failure may be 
masked, and therefore LTRs may be oligosymptomatic 
despite advanced cardiac/coronary heart disease. With 
increasing age and survival, detection of relevant cardio-
vascular morbidity requires respective investigations 
whereby the less invasive procedures are preferred. Pul-
monary embolus should be considered in LTRs with un-
explained pulmonary symptoms or evidence of throm-
boembolic events such as deep vein thrombosis in the 
extremities (on duplex sonography). We prefer scinti-
graphic evaluations and avoid contrasted CT scans in or-
der to preserve kidney function.
 With regard to fluid balance, oedema and heart failure 
management, diuretics may be part of the anti-hyperten-
sive regimen, but the hydration status must be considered 
in all LTRs since overly aggressive diuretic treatment may 
enhance renal failure due to a pre-renal component, more 
so than in non-transplanted patients  [72] . We tend to en-
courage our patients to drink sufficient liquids on a regu-
lar basis (depending on age and co-morbidity, the amount 
is individually defined between 2 and 4 litres/day) and 
adjust diuretics and anti-hypertensive and heart failure 
drugs to the steady state obtained in a constant hydration 
status. In this context, daily weight measurement and 
consideration of drug adjustments is essential. Reduced 
oncotic pressure may contribute to these problems with 
loss of fluids into the third space. We generally investigate 
for renal protein losses when other more obvious causes 
have been ruled out. Renal loss of magnesium is increased 
with CNI use (cyclosporine or tacrolimus), thus necessi-
tating sufficient magnesium supplementation for all pa-
tients.
 Dyslipidaemia is a common problem in LTRs and a 
known adverse effect of CNI treatment. Pravastatin is the 
drug with the smallest interaction potential in this con-
text and is therefore the drug of our choice. Long-term 
cardiovascular complications are seen especially in long-
term survivors and influence overall survival  [5] .
 Surgery and Other Invasive Procedures 
 Surgical interventions go along with an inherent in-
creased risk of complications, which in our experience is 
substantially increased when compared to non-trans-
plant patients. Intra-abdominal problems in LTRs re-
quiring surgical intervention are associated with a rele-
vantly increased mortality  [60] . This is well documented 
for emergent surgery and/or surgery involving septic 
complications  [60, 65] . Any kind of surgical intervention 
should therefore be prepared well in advance, particu-
larly in elective cases. The most frequent complications 
we observe are peri-operative deterioration due to a com-
bination of fluid imbalance/hypertensive blood pressure 
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measurements and attempts to correct these with subse-
quent worsening renal function and sometimes acute 
heart failure. This is likely related to the disruption of 
pulmonary lymphatics and bronchial circulation leading 
to an increased risk of pulmonary oedema  [72, 73] . There-
fore, fluid management should be conservative in the 
peri-operative setting, and diuretics should be prescribed 
if necessary  [70] . GOR with microaspiration, pulmonary 
and non-pulmonary infections, wound healing prob-
lems, excessive bleeding, intestinal obstruction and need 
for re-operation are quite common, even in the hands of 
very experienced surgeons and anaesthetists. If possible, 
we prefer primarily conservative strategies rather than a 
surgical intervention and draw attention to the pitfalls by 
communicating the ‘seven sins list’ ( table 5 ) to surgical 
and anaesthetic colleagues when surgical intervention is 
inevitable. We assist in the planning of surgery and man-
agement of our LTRs when surgery appears to be the only 
feasible solution, including advice on peri-operative anti-
biotics, securing an intensive care unit bed for post-oper-
ative care and engaging an anaesthetist who is familiar 
with the potential complications of LTRs undergoing sur-
gery  [32, 72, 73] . Most of these precautions are respected 
no matter how small the intervention may appear. Close 
interaction with the transplant team is likely the single 
most important step in preparing the transplanted pa-
tient for surgery and successfully managing their post-
operative care  [70] .
 In summary, LTRs react somewhat differently to a 
number of external influences including infections, 
 medication and diagnostic or therapeutic interventions. 
These patients may present in emergency situations with 
strikingly few symptoms. These aspects require an expe-
rienced team for patient management since complica-
tions are more common in these frequently healthy-look-
ing patients. We believe our paper draws attention to 
some of the pitfalls and possible strategies to prevent 
common complications in LTRs and thus may contribute 
to better understanding and treatment of LTRs.
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Table 5.  ‘Seven sins’ relating to invasive procedures in LTRs
1. Wrong indication or dismissal of conservative strategy. Invasive interventions in situations that may have possibly resolved with 
consequent conservative measures (‘using standard indications for non-standard patients!’).
2. Lack of meticulous preparation of procedure involving all possible specialists that may be of relevance (including lung transplant 
specialist, anaesthetist, experienced surgeon familiar with high complication rate of this population, experienced intensivist for 
post-operative care) [18, 70].
3. Lack of intravenous anti-infective treatment for at least 2–3 days before and after the surgical intervention (in collaboration with 
lung transplant specialist).
4. Lack of early and consequent laxative treatment to prevent intestinal complications. Avoid opioids for this reason.
5. Lack of cautious blood pressure control and fluid management; lack of experience with technicalities and pitfalls of blood pressure 
measurement and control in this population can severely complicate any intervention (arterial hypertension is highly prevalent 
among LTRs, and many require multiple anti-hypertensives for adequate blood pressure control). Fluid intake should not be 
restricted pre-operatively to avoid haemodynamic instability and renal dysfunction. Fluid overload should be avoided intra-
operatively due to impaired lymphatic drainage [32, 72, 73].
6. Lack of strict anti-reflux measures to prevent GOR and aspiration, such as positioning the patient in the ‘tilt position’ (reverse 
Trendelenburg position) at all times irrespective of circumstances, and no enteral feeds via the gastric tube (duodenal or jejunal 
tube feeding only) [32, 73].
7. Non-anticipation of possible complications (kidney failure due to contrast agent or non-steroidal anti-rheumatics) and failure to 
implement preventive strategies including having an intensive care unit bed on ‘stand-by’ for all LTRs post-operatively [72].
T his list is applicable to any kind of management procedure relating to LTRs but is specifically true when invasive procedures are 
anticipated.
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